- Robert Ingram has been appointed chief executive of Glaxo Wellcomeplc. Mr Ingram will retain his role as president and chief executive of the company's subsidiary in the USA, Glaxo Wellcome Inc. In addition, he will also take over the chairmanship of Glaxo Wellcome Inc and Nippon Glaxo in Japan from Sir Richard Sykes, who remains chairman of Glaxo Wellcome plc. As a result of this decision, chief operating officer Sean Lance, who it was presumed would take the CEO post, has resigned.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze